Ado-trastuzumab Emtansine (Kadcyla®)

OncoLink Team
Ultima Vez Modificado: 20 de julio del 2015

Translation for this article does not exist


Click on any of these terms for more related articles


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

FDA Approves Kadcyla for Late-Stage Breast Cancer

Feb 25, 2013

Fourth drug approved targeting HER2 protein; slows disease progression, prolongs survival

ASCO: T-DM1 Ups Progression-Free Survival in Breast Cancer

Jun 5, 2012

T-DM1 is a well-tolerated, novel therapy for HER2+ advanced breast cancer patients

Chemo, Trastuzumab, Surgery Up Survival in HER2-Positive MBC

Jul 19, 2011

After adjustment, only chemo, trastuzumab linked to survival for patients with CNS metastases